2. Academic Validation
  3. Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa

Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa

  • Antimicrob Agents Chemother. 2023 May 31;e0033923. doi: 10.1128/aac.00339-23.
Christophe Le Terrier 1 2,  Patrice Nordmann 1 3 4,  Charlotte Freret 1,  Marion Seigneur 1,  Laurent Poirel 1 3
Affiliations

Affiliations

  • 1 Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
  • 2 Division of Intensive care unit, University hospitals of Geneva, Geneva, Switzerland.
  • 3 Swiss National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland.
  • 4 University of Lausanne and University hospital Center, Lausanne, Switzerland.
PMID: 37255469 DOI: 10.1128/aac.00339-23
Abstract

The impact of broad-spectrum β-lactamases on the susceptibility to novel β-lactamase/β-lactamase inhibitor combinations was evaluated both in Pseudomonas aeruginosa and Escherichia coli using isogenic backgrounds. Cefepime-zidebactam displayed low MICs, mainly due to the significant intrinsic Antibacterial activity of zidebactam. Cefepime-taniborbactam showed excellent activity against recombinant E. coli strains, including metallo-β-lactamase producers, whereas aztreonam-avibactam remained the best therapeutic option against class B β-lactamase-producing P. aeruginosa.

Keywords

avibactam; enmetazobactam; nacubactam; relebactam; susceptibility testing; taniborbactam; vaborbactam; zidebactam; β-lactamase.

Figures
Products